Materiały źródłowe

• #1 Neuroblastoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK448111/

  Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months. It accounts for 15% of pediatric cancer-related deaths. The annual incidence of neuroblastoma in the United States is approximately 650 cases, i.e., 10.2 per million children (65 per million infants), with little change (0.4%) over time. While an overall improvement in five-year mortality has been noted between 1975 through 2005, subgroup-specific mortality paints a different picture. […] The widespread variability in neuroblastoma tumor behavior is linked to multiple factors now linked with patient prognosis. Classic prognostic categorization by Childrens Oncology Group (COG) divides patients into four groups based on patient age, post-surgical stage, MYCN amplification, histology, and DNA ploidy. Over 50% of newly diagnosed neuroblastoma are very-low or low-risk. Negative prognostic markers include age older than 18 months, metastasis at diagnosis, and presence of MYCN amplification, 1p loss, 11q loss, 17q gain, or DNA copy number alterations.

• #2 Neuroblastoma – Wikipedia

  https://en.wikipedia.org/wiki/Neuroblastoma

  Neuroblastoma comprises 6-10% of all childhood cancers, and 15% of cancer deaths in children. The annual mortality rate is 10 per million children in the 0- to 4-year-old age group, and 4 per million in the 4- to 9-year old age group. […] The highest number of cases is in the first year of life, and some cases are congenital. The age range is broad, including older children and adults, but only 10% of cases occur in people older than 5 years of age. A large European study reported less than 2% of over 4000 neuroblastoma cases were over 18 years old.

• #3 Neuroblastoma Market Size, Trends and Forecast 2024-2034

  https://www.imarcgroup.com/neuroblastoma-market

  Neuroblastoma affects 10.2 children per million under the age of 15, with almost 500 new cases diagnosed each year. […] Neuroblastomas are diagnosed in around nine out of ten children by the age of five. […] Neuroblastoma is more common in white people and somewhat more prevalent in males than in girls (male-to-female ratio of 1.3:1). […] Neuroblastoma causes roughly 15% of all cancer-related fatalities in the pediatric population. […] Every year, approximately 700 to 800 new cases of neuroblastoma are diagnosed in the United States.

• #4 Neuroblastoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK448111/

  Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months. It accounts for 15% of pediatric cancer-related deaths. The annual incidence of neuroblastoma in the United States is approximately 650 cases, i.e., 10.2 per million children (65 per million infants), with little change (0.4%) over time. While an overall improvement in five-year mortality has been noted between 1975 through 2005, subgroup-specific mortality paints a different picture. […] The widespread variability in neuroblastoma tumor behavior is linked to multiple factors now linked with patient prognosis. Classic prognostic categorization by Childrens Oncology Group (COG) divides patients into four groups based on patient age, post-surgical stage, MYCN amplification, histology, and DNA ploidy. Over 50% of newly diagnosed neuroblastoma are very-low or low-risk. Negative prognostic markers include age older than 18 months, metastasis at diagnosis, and presence of MYCN amplification, 1p loss, 11q loss, 17q gain, or DNA copy number alterations.

• #5 Key Statistics for Neuroblastoma | Neuroblastoma Stats | American Cancer Society

  https://www.cancer.org/cancer/types/neuroblastoma/about/key-statistics.html

  Neuroblastoma is by far the most common cancer in infants (younger than 1 year old). There are about 700 to 800 new cases of neuroblastoma each year in the United States. This number has remained about the same for many years. […] The average age of children when they are diagnosed is about 1 to 2 years. Rarely, neuroblastoma is detected by ultrasound even before birth. About 9 out of 10 neuroblastomas are diagnosed by age 5. It is rare in people over the age of 10 years.

• #6 Neuroblastoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq

  Neuroblastoma is the most common extracranial solid tumor in childhood. More than 650 cases are diagnosed each year in the United States. The prevalence is about 1 case per 7,000 live births. The incidence is 8.3 cases per 1 million per year in children younger than 15 years. The overall incidence of neuroblastoma cases in the United States has remained stable. About 37% of patients are diagnosed as infants, and 90% are younger than 5 years at diagnosis, with a median age at diagnosis of 17 months. The data on age at diagnosis show that this is a disease of infancy, with the highest rate of diagnosis in the first month of life. […] The United States Cancer Statistics database and the National Program of Cancer Registries survival database were used to describe epidemiological trends in incidence and outcomes in patients with neuroblastoma between 2003 and 2019. Non-Hispanic White patients have a higher risk of developing neuroblastoma than all other race and ethnicity groups. Compared with non-Hispanic White patients, the relative risks were 0.54 for Hispanic patients, 0.64 for non-Hispanic Asian or Pacific Islander patients, 0.69 for non-Hispanic American Indian and Alaska Native patients, and 0.73 for non-Hispanic Black patients. The 5-year relative survival rates were higher for non-Hispanic White patients (80.7%) and Hispanic patients (80.8%), compared with non-Hispanic Black patients (72.6%). […] Findings from epidemiological studies have not unequivocally linked environmental or other exposures to increased or decreased incidences of neuroblastoma.

• #7 Neuroblastoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK448111/

  Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months. It accounts for 15% of pediatric cancer-related deaths. The annual incidence of neuroblastoma in the United States is approximately 650 cases, i.e., 10.2 per million children (65 per million infants), with little change (0.4%) over time. While an overall improvement in five-year mortality has been noted between 1975 through 2005, subgroup-specific mortality paints a different picture. […] The widespread variability in neuroblastoma tumor behavior is linked to multiple factors now linked with patient prognosis. Classic prognostic categorization by Childrens Oncology Group (COG) divides patients into four groups based on patient age, post-surgical stage, MYCN amplification, histology, and DNA ploidy. Over 50% of newly diagnosed neuroblastoma are very-low or low-risk. Negative prognostic markers include age older than 18 months, metastasis at diagnosis, and presence of MYCN amplification, 1p loss, 11q loss, 17q gain, or DNA copy number alterations.

• #8 Neuroblastoma: Practice Essentials, Background, Relevant Anatomy

  https://emedicine.medscape.com/article/439263-overview

  Neuroblastoma is the most common cancer in infants. Approximately 700-800 cases are diagnosed each year in the United States, accounting for about 6% of cancers in children. […] Neuroblastoma is more common in whites and is slightly more prevalent in boys than in girls (male-to-female ratio of 1.3:1). In rare cases, neuroblastoma is detected by prenatal ultrasound. About 37% of cases are diagnosed in infancy, and nearly 90% of cases are diagnosed before the age of 5 years. Median age at diagnosis is 19 months. […] Neuroblastoma is rare in people over the age of 10 years. Neuroblastoma is thought to occur sporadically, with 1-2% of cases considered familial.

• #9 Neuroblastoma | 5-Minute Pediatric Consult

  https://peds.unboundmedicine.com/pedscentral/view/5-Minute-Pediatric-Consult/617742/all/Neuroblastoma?q=Pallor

  Neuroblastoma is a small round blue cell tumor of childhood which arises from developing neural crest cells in the sympathetic nervous system. […] The median age at diagnosis is 19 months, with 89% of cases diagnosed 5 years of age. Fewer than 5% of patients are diagnosed 10 years of age. […] About 800 new cases per year in the United States (10 per million children per year). […] Accounts for 810% of all childhood cancer, making it the most common extracranial solid tumor and the most common cancer overall during the first 2 years of life. […] Occurs in 1 per 7,000 live births.

• #10 Neuroblastoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq

  Neuroblastoma is the most common extracranial solid tumor in childhood. More than 650 cases are diagnosed each year in the United States. The prevalence is about 1 case per 7,000 live births. The incidence is 8.3 cases per 1 million per year in children younger than 15 years. The overall incidence of neuroblastoma cases in the United States has remained stable. About 37% of patients are diagnosed as infants, and 90% are younger than 5 years at diagnosis, with a median age at diagnosis of 17 months. The data on age at diagnosis show that this is a disease of infancy, with the highest rate of diagnosis in the first month of life. […] The United States Cancer Statistics database and the National Program of Cancer Registries survival database were used to describe epidemiological trends in incidence and outcomes in patients with neuroblastoma between 2003 and 2019. Non-Hispanic White patients have a higher risk of developing neuroblastoma than all other race and ethnicity groups. Compared with non-Hispanic White patients, the relative risks were 0.54 for Hispanic patients, 0.64 for non-Hispanic Asian or Pacific Islander patients, 0.69 for non-Hispanic American Indian and Alaska Native patients, and 0.73 for non-Hispanic Black patients. The 5-year relative survival rates were higher for non-Hispanic White patients (80.7%) and Hispanic patients (80.8%), compared with non-Hispanic Black patients (72.6%). […] Findings from epidemiological studies have not unequivocally linked environmental or other exposures to increased or decreased incidences of neuroblastoma.

• #11 Neuroblastoma: Practice Essentials, Background, Relevant Anatomy

  https://emedicine.medscape.com/article/439263-overview

  Neuroblastoma is the most common cancer in infants. Approximately 700-800 cases are diagnosed each year in the United States, accounting for about 6% of cancers in children. […] Neuroblastoma is more common in whites and is slightly more prevalent in boys than in girls (male-to-female ratio of 1.3:1). In rare cases, neuroblastoma is detected by prenatal ultrasound. About 37% of cases are diagnosed in infancy, and nearly 90% of cases are diagnosed before the age of 5 years. Median age at diagnosis is 19 months. […] Neuroblastoma is rare in people over the age of 10 years. Neuroblastoma is thought to occur sporadically, with 1-2% of cases considered familial.

• #12 Neuroblastoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq

  Neuroblastoma is the most common extracranial solid tumor in childhood. More than 650 cases are diagnosed each year in the United States. The prevalence is about 1 case per 7,000 live births. The incidence is 8.3 cases per 1 million per year in children younger than 15 years. The overall incidence of neuroblastoma cases in the United States has remained stable. About 37% of patients are diagnosed as infants, and 90% are younger than 5 years at diagnosis, with a median age at diagnosis of 17 months. The data on age at diagnosis show that this is a disease of infancy, with the highest rate of diagnosis in the first month of life. […] The United States Cancer Statistics database and the National Program of Cancer Registries survival database were used to describe epidemiological trends in incidence and outcomes in patients with neuroblastoma between 2003 and 2019. Non-Hispanic White patients have a higher risk of developing neuroblastoma than all other race and ethnicity groups. Compared with non-Hispanic White patients, the relative risks were 0.54 for Hispanic patients, 0.64 for non-Hispanic Asian or Pacific Islander patients, 0.69 for non-Hispanic American Indian and Alaska Native patients, and 0.73 for non-Hispanic Black patients. The 5-year relative survival rates were higher for non-Hispanic White patients (80.7%) and Hispanic patients (80.8%), compared with non-Hispanic Black patients (72.6%). […] Findings from epidemiological studies have not unequivocally linked environmental or other exposures to increased or decreased incidences of neuroblastoma.

• #13 Neuroblastoma: Practice Essentials, Background, Relevant Anatomy

  https://emedicine.medscape.com/article/439263-overview

  Neuroblastoma is the most common cancer in infants. Approximately 700-800 cases are diagnosed each year in the United States, accounting for about 6% of cancers in children. […] Neuroblastoma is more common in whites and is slightly more prevalent in boys than in girls (male-to-female ratio of 1.3:1). In rare cases, neuroblastoma is detected by prenatal ultrasound. About 37% of cases are diagnosed in infancy, and nearly 90% of cases are diagnosed before the age of 5 years. Median age at diagnosis is 19 months. […] Neuroblastoma is rare in people over the age of 10 years. Neuroblastoma is thought to occur sporadically, with 1-2% of cases considered familial.

• #14 Neuroblastoma : Epidemiology

  https://www.webpathology.com/images/endocrine/adrenal/neuroblastoma/41665

  Neuroblastoma is the most common extra-cranial solid tumor in childhood. It makes up almost 7% of all cancers in children under 15 years of age in the U.S. Almost 90% of patients are younger than 5 years at diagnosis and 98% are diagnosed by the age of 10 years. The median age at diagnosis is 19 months. About 1% to 2% of neuroblastomas are familial. Familial cases appear to have an autosomal dominant pattern of inheritance and are diagnosed much earlier than sporadic cases at a median age of 9 months. […] Rare cases have been documented in adults. There are some well-established associations, including Beckwith-Wiedemann syndrome, Hirschsprung disease, Neurofibromatosis, and as a complication of Fetal Hydantoin syndrome. […] Bilaterality and multifocality is more common in familial cases.

• #15 Neuroblastoma: Practice Essentials, Background, Relevant Anatomy

  https://emedicine.medscape.com/article/439263-overview

  Neuroblastoma is the most common cancer in infants. Approximately 700-800 cases are diagnosed each year in the United States, accounting for about 6% of cancers in children. […] Neuroblastoma is more common in whites and is slightly more prevalent in boys than in girls (male-to-female ratio of 1.3:1). In rare cases, neuroblastoma is detected by prenatal ultrasound. About 37% of cases are diagnosed in infancy, and nearly 90% of cases are diagnosed before the age of 5 years. Median age at diagnosis is 19 months. […] Neuroblastoma is rare in people over the age of 10 years. Neuroblastoma is thought to occur sporadically, with 1-2% of cases considered familial.

• #16 Neuroblastoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Neuroblastoma_epidemiology_and_demographics

  Neuroblastoma is the most common solid extracranial cancer in childhood and is the most common cancer in infancy. The overall incidence is 4.9 per 1,000,000 individuals in United states. Males are slightly more affected than females with 1.2:1 ratio. The incidence of neuroblastoma decreases with age and the highest incidence is in the first year of life. Neuroblastoma usually affects individuals of the Caucasian race. […] The overall incidence rate of neuroblastoma is approximately 4.9 per 1,000,000 individuals in the United States. […] Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy. […] The incidence of neuroblastoma decreases with age; the highest incidence is in the first year of life. […] Males are slightly more commonly affected with neuroblastoma than females. The male to female ratio is approximately 1.12 to 1.

• #17 Neuroblastoma Market Size, Trends and Forecast 2024-2034

  https://www.imarcgroup.com/neuroblastoma-market

  Neuroblastoma affects 10.2 children per million under the age of 15, with almost 500 new cases diagnosed each year. […] Neuroblastomas are diagnosed in around nine out of ten children by the age of five. […] Neuroblastoma is more common in white people and somewhat more prevalent in males than in girls (male-to-female ratio of 1.3:1). […] Neuroblastoma causes roughly 15% of all cancer-related fatalities in the pediatric population. […] Every year, approximately 700 to 800 new cases of neuroblastoma are diagnosed in the United States.

• #18 Neuroblastoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Neuroblastoma_epidemiology_and_demographics

  The incidence rate of neuroblastoma among males is approximately 5.1 per 1,000,000 individuals in the United States. […] The incidence rate of neuroblastoma among females is approximately 4.6 per 1,000,000 individuals in the United States. […] Neuroblastoma usually affects individuals of the Caucasian race. African Americans, Native Indians, and Asians are less likely to develop neuroblastoma. […] The incidence rate of neuroblastoma among Caucasians is approximately 5.1 per 1,000,000 individuals in the United States. […] The incidence rate of neuroblastoma among African Americans is approximately 4.1 per 1,000,000 individuals in the United States. […] The overall incidence rate of neuroblastoma among Native Indians and Asians is approximately 3.8 per 1,000,000 individuals in the United States.

• #19 Neuroblastoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq

  Neuroblastoma is the most common extracranial solid tumor in childhood. More than 650 cases are diagnosed each year in the United States. The prevalence is about 1 case per 7,000 live births. The incidence is 8.3 cases per 1 million per year in children younger than 15 years. The overall incidence of neuroblastoma cases in the United States has remained stable. About 37% of patients are diagnosed as infants, and 90% are younger than 5 years at diagnosis, with a median age at diagnosis of 17 months. The data on age at diagnosis show that this is a disease of infancy, with the highest rate of diagnosis in the first month of life. […] The United States Cancer Statistics database and the National Program of Cancer Registries survival database were used to describe epidemiological trends in incidence and outcomes in patients with neuroblastoma between 2003 and 2019. Non-Hispanic White patients have a higher risk of developing neuroblastoma than all other race and ethnicity groups. Compared with non-Hispanic White patients, the relative risks were 0.54 for Hispanic patients, 0.64 for non-Hispanic Asian or Pacific Islander patients, 0.69 for non-Hispanic American Indian and Alaska Native patients, and 0.73 for non-Hispanic Black patients. The 5-year relative survival rates were higher for non-Hispanic White patients (80.7%) and Hispanic patients (80.8%), compared with non-Hispanic Black patients (72.6%). […] Findings from epidemiological studies have not unequivocally linked environmental or other exposures to increased or decreased incidences of neuroblastoma.

• #20 Neuroblastoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Neuroblastoma_epidemiology_and_demographics

  The incidence rate of neuroblastoma among males is approximately 5.1 per 1,000,000 individuals in the United States. […] The incidence rate of neuroblastoma among females is approximately 4.6 per 1,000,000 individuals in the United States. […] Neuroblastoma usually affects individuals of the Caucasian race. African Americans, Native Indians, and Asians are less likely to develop neuroblastoma. […] The incidence rate of neuroblastoma among Caucasians is approximately 5.1 per 1,000,000 individuals in the United States. […] The incidence rate of neuroblastoma among African Americans is approximately 4.1 per 1,000,000 individuals in the United States. […] The overall incidence rate of neuroblastoma among Native Indians and Asians is approximately 3.8 per 1,000,000 individuals in the United States.

• #21 Neuroblastoma epidemiology and demographics – wikidoc

  https://www.wikidoc.org/index.php/Neuroblastoma_epidemiology_and_demographics

  The incidence rate of neuroblastoma among males is approximately 5.1 per 1,000,000 individuals in the United States. […] The incidence rate of neuroblastoma among females is approximately 4.6 per 1,000,000 individuals in the United States. […] Neuroblastoma usually affects individuals of the Caucasian race. African Americans, Native Indians, and Asians are less likely to develop neuroblastoma. […] The incidence rate of neuroblastoma among Caucasians is approximately 5.1 per 1,000,000 individuals in the United States. […] The incidence rate of neuroblastoma among African Americans is approximately 4.1 per 1,000,000 individuals in the United States. […] The overall incidence rate of neuroblastoma among Native Indians and Asians is approximately 3.8 per 1,000,000 individuals in the United States.

• #22 The Epidemiology of Neuroblastoma by Stefano Parodi (2008-10-31): Stefano Parodi: Amazon.com: Books

  https://www.amazon.com/Epidemiology-Neuroblastoma-Stefano-Parodi-2008-10-31/dp/B01K05XKOW

  Neuroblastoma is a cancer of the sympathetic nervous system. It is the most common tumor in the first year of life and the most common solid extra-cranial cancer in childhood. […] In Western countries its incidence varies between 7 and 16 cases per million children and it tends to decrease increasing the age. […] The first part of this monograph collects the more recent information about the Descriptive Epidemiology of Neuroblastoma, providing a picture of its geographical distribution worldwide and describing the related time trend.

• #23 Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981–2000: a population-based study | British Journal of Cancer

  https://www.nature.com/articles/6604922

  Neuroblastoma is the most frequent solid tumour outside the central nervous system in children below 15 years of age in Denmark with an annual incidence of 810 new cases. […] The incidence was 8.55 per million children below 15 years of age (world standard 9.6) and 42.6 per million children below 12 months of age, and it has remained unchanged since 1970. […] We aimed to investigate whether neuroblastoma during the period 19812000 showed changes in incidence and mortality rate since the earlier population-based study in Denmark. […] The incidence of all neuroblastomas during 19812000, by age and period, are shown in Table 2, with that in children below 15 years being 8.55 per million and 9.6 per million being age standardised. There was no difference in incidence between the two 10-year periods

• #24 Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981–2000: a population-based study | British Journal of Cancer

  https://www.nature.com/articles/6604922

  In this population-based study of neuroblastoma in Denmark over a 20-year period, the age-standardised incidence was 9.6 per million overall and 42.6 per million below 12 months of age at diagnosis, similar to those found in Denmark during 19761980 […] A considerable part of the improved prognosis from the first to the second 10-year period could be attributed to a significantly decreased early mortality, especially during the first 6 months after diagnosis during the second period. […] Our analyses also showed a significantly increased survival of children over 12 months with stage 4 neuroblastoma treated after 1990, in which autologous stem cell transplantation (ASCT) was introduced compared with the earlier period. […] In a population-based study of all cases of neuroblastoma in Denmark during 19812000, no increase in incidence and no change in the distribution of prognostic factors were shown compared with a study up to 1980.

• #25 Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981–2000: a population-based study | British Journal of Cancer

  https://www.nature.com/articles/6604922

  Neuroblastoma is the most frequent solid tumour outside the central nervous system in children below 15 years of age in Denmark with an annual incidence of 810 new cases. […] The incidence was 8.55 per million children below 15 years of age (world standard 9.6) and 42.6 per million children below 12 months of age, and it has remained unchanged since 1970. […] We aimed to investigate whether neuroblastoma during the period 19812000 showed changes in incidence and mortality rate since the earlier population-based study in Denmark. […] The incidence of all neuroblastomas during 19812000, by age and period, are shown in Table 2, with that in children below 15 years being 8.55 per million and 9.6 per million being age standardised. There was no difference in incidence between the two 10-year periods

• #26 Global Neuroblastoma Markets, Epidemiology and Patient Flow Report 2020-2035 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210514005189/en/Global-Neuroblastoma-Markets-Epidemiology-and-Patient-Flow-Report-2020-2035—ResearchAndMarkets.com

  Global Neuroblastoma Epidemiology and Patient Flow Analysis – 2021, provides Neuroblastoma epidemiology, demographics, and patient flow. The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan. […] The research provides population data to characterize Neuroblastoma patients, history of the disease at the population level (Neuroblastoma prevalence, Neuroblastoma incidence) and at the clinical level (from diagnosis to treated patients). […] Forecast: Neuroblastoma epidemiology forecast to 2035. […] US Neuroblastoma Epidemiology and Patient Flow […] Germany Neuroblastoma Epidemiology and Patient Flow […] France Neuroblastoma Epidemiology and Patient Flow […] Italy Neuroblastoma Epidemiology and Patient Flow […] Spain Neuroblastoma Epidemiology and Patient Flow […] UK Neuroblastoma Epidemiology and Patient Flow […] Europe Neuroblastoma Epidemiology and Patient Flow […] Japan Neuroblastoma Epidemiology and Patient Flow […] Global Neuroblastoma Epidemiology and Patient Flow.

• #27 Neuroblastoma – Epidemiology Forecast to 2032

  https://www.researchandmarkets.com/reports/4520736/neuroblastoma-epidemiology-forecast-to-2032?srsltid=AfmBOoqRkd4nfCbJ83q9cqTg5hXCrUneFYbUpgmtAk5X0RazOf_15qOC

  This „Neuroblastoma – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Neuroblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. […] The Neuroblastoma epidemiology report gives a thorough understanding of the Neuroblastoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Neuroblastoma in the US, Europe, and Japan. The report covers the detailed information of the Neuroblastoma epidemiology scenario in seven major countries (US, EU5, and Japan). […] The Neuroblastoma epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Neuroblastoma epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Neuroblastoma epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

• #28

  https://clarivate.com/life-sciences-healthcare/report/epidon0159-biopharma-neuroblastoma-epidemiology-emerging-markets/

  Clarivate Epidemiologys coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. […] We report both the incidence and prevalence of neuroblastoma for each country, as well as annualized case counts projected to the national population. […] Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. […] Clarivate Epidemiology forecasts the following neuroblastoma patient populations: Diagnosed incident cases. Diagnosed incident cases of localized disease. Diagnosed incident cases of regional disease. Diagnosed incident cases of distant disease. Diagnosed incident cases of metastatic recurrent disease. Diagnosed prevalent cases. Diagnosed first-line drug-treatable population. […] How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of neuroblastoma over the forecast period?

• #29 Neuroblastoma: Practice Essentials, Background, Relevant Anatomy

  https://emedicine.medscape.com/article/439263-overview

  Neuroblastoma is the most common cancer in infants. Approximately 700-800 cases are diagnosed each year in the United States, accounting for about 6% of cancers in children. […] Neuroblastoma is more common in whites and is slightly more prevalent in boys than in girls (male-to-female ratio of 1.3:1). In rare cases, neuroblastoma is detected by prenatal ultrasound. About 37% of cases are diagnosed in infancy, and nearly 90% of cases are diagnosed before the age of 5 years. Median age at diagnosis is 19 months. […] Neuroblastoma is rare in people over the age of 10 years. Neuroblastoma is thought to occur sporadically, with 1-2% of cases considered familial.

• #30 Neuroblastoma Predisposition and Surveillance-An Update from the 2023 AACR Childhood Cancer Predisposition Workshop – PubMed

  https://pubmed.ncbi.nlm.nih.gov/38860978/

  Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary tumors, and occasional patients have syndromes that are associated with increased NB risk. […] We review the evidence for all these genes and whether there is sufficient evidence to warrant surveillance. We review recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017.

• #31 Risk factors for neuroblastoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/neuroblastoma/risks

  Neuroblastoma is the most common solid tumour outside of the brain in children. It accounts for 8% to 10% of all cancers in children. […] About 80% of neuroblastomas occur in children under the age of 5, and the average age at diagnosis is 2.5 years. It is the most common cancer in babies under the age of 1 year. Neuroblastoma is very rare in children over 10 years of age. This cancer occurs slightly more often in boys than in girls. […] There is convincing evidence that the following factors increase the risk for neuroblastoma. […] About 1% to 2% of children diagnosed with neuroblastoma have a family history of the disease. The risk for neuroblastoma seems to be highest for siblings or an identical twin of children who already have the disease. In most children with a family history of neuroblastoma, there are genetic mutations in the anaplastic lymphoma kinase (ALK) gene.

• #32 Neuroblastoma Predisposition and Surveillance-An Update from the 2023 AACR Childhood Cancer Predisposition Workshop – PubMed

  https://pubmed.ncbi.nlm.nih.gov/38860978/

  Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary tumors, and occasional patients have syndromes that are associated with increased NB risk. […] We review the evidence for all these genes and whether there is sufficient evidence to warrant surveillance. We review recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017.

• #33 Neuroblastoma Predisposition and Surveillance—An Update from the 2023 AACR Childhood Cancer Predisposition Workshop

  https://ouci.dntb.gov.ua/en/works/lRwVzgK9/

  Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary tumors, and occasional patients have syndromes that are associated with increased NB risk. […] We review the evidence for all these genes and whether there is sufficient evidence to warrant surveillance. We review recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017. […] Guidelines for surveillance in this population were published in 2017, and recently, members of the American Association for Cancer Research Pediatric Cancer Working Group met to update those guidelines with a review of more recently published evidence and risk estimates.

• #34 Risk factors for neuroblastoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/neuroblastoma/risks

  Children with the following genetic conditions have a higher risk of developing neuroblastoma. […] Children with neurofibromatosis type 1 have a higher risk of developing certain cancers, including neuroblastoma. […] Children with Beckwith-Wiedemann syndrome have a higher risk of developing certain cancers, including neuroblastoma. […] Li-Fraumeni syndrome greatly increases a child’s risk of developing several types of cancer, including neuroblastoma. […] Children with Costello syndrome have a higher risk of developing certain cancers, including neuroblastoma.

• #35 Risk factors for neuroblastoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/neuroblastoma/risks

  Children with the following genetic conditions have a higher risk of developing neuroblastoma. […] Children with neurofibromatosis type 1 have a higher risk of developing certain cancers, including neuroblastoma. […] Children with Beckwith-Wiedemann syndrome have a higher risk of developing certain cancers, including neuroblastoma. […] Li-Fraumeni syndrome greatly increases a child’s risk of developing several types of cancer, including neuroblastoma. […] Children with Costello syndrome have a higher risk of developing certain cancers, including neuroblastoma.

• #36 Neuroblastoma : Epidemiology

  https://www.webpathology.com/images/endocrine/adrenal/neuroblastoma/41665

  Neuroblastoma is the most common extra-cranial solid tumor in childhood. It makes up almost 7% of all cancers in children under 15 years of age in the U.S. Almost 90% of patients are younger than 5 years at diagnosis and 98% are diagnosed by the age of 10 years. The median age at diagnosis is 19 months. About 1% to 2% of neuroblastomas are familial. Familial cases appear to have an autosomal dominant pattern of inheritance and are diagnosed much earlier than sporadic cases at a median age of 9 months. […] Rare cases have been documented in adults. There are some well-established associations, including Beckwith-Wiedemann syndrome, Hirschsprung disease, Neurofibromatosis, and as a complication of Fetal Hydantoin syndrome. […] Bilaterality and multifocality is more common in familial cases.

• #37 Risk factors for neuroblastoma | Canadian Cancer Society

  https://cancer.ca/en/cancer-information/cancer-types/neuroblastoma/risks

  Neuroblastoma is the most common solid tumour outside of the brain in children. It accounts for 8% to 10% of all cancers in children. […] About 80% of neuroblastomas occur in children under the age of 5, and the average age at diagnosis is 2.5 years. It is the most common cancer in babies under the age of 1 year. Neuroblastoma is very rare in children over 10 years of age. This cancer occurs slightly more often in boys than in girls. […] There is convincing evidence that the following factors increase the risk for neuroblastoma. […] About 1% to 2% of children diagnosed with neuroblastoma have a family history of the disease. The risk for neuroblastoma seems to be highest for siblings or an identical twin of children who already have the disease. In most children with a family history of neuroblastoma, there are genetic mutations in the anaplastic lymphoma kinase (ALK) gene.

• #38 Pediatric Neuroblastoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988284-followup

  Currently, no specific recommendations on how to prevent this disease are known. […] Screening for neuroblastoma in an attempt to diagnose high-risk patients earlier in the course of their disease has uncovered many patients with low-risk disease but has not had an impact on outcome in high-risk disease.

• #39

  https://journals.lww.com/jpho-online/abstract/1992/05000/neuroblastoma__epidemiology_and_pattern_of.3.aspx

  Neuroblastomas are malignant, embryonic tumors, and most are probably congenital in origin. […] Epidemiological data suggest that, in recent decades, borderline lesions may be included among truly malignant neuroblastomas. The recent birth cohorts compiled in Denmark show that 1 in 7,000 live births will develop neuroblastoma before 15 years of age. […] However, the proof that screening can only detect lesions that would have progressed to become malignant tumors depends on observing an appropriate fall in the incidence of the malignant tumors in older children and a decline in mortality. Therefore, it is of some concern that the incidence of neuroblastomas appears to actually increase with screening while mortality has been little effected.

• #40 Neuroblastoma Predisposition and Surveillance—An Update from the 2023 AACR Childhood Cancer Predisposition Workshop

  https://ouci.dntb.gov.ua/en/works/lRwVzgK9/

  Genetic predisposition to neuroblastoma (NB) is relatively rare. Only 1% to 2% of patients have a family history of NB, 3% to 4% of cases present with bilateral or multifocal primary tumors, and occasional patients have syndromes that are associated with increased NB risk. […] We review the evidence for all these genes and whether there is sufficient evidence to warrant surveillance. We review recommended surveillance for hereditary patients with NB, including minor updates to surveillance recommendations that were published previously in 2017. […] Guidelines for surveillance in this population were published in 2017, and recently, members of the American Association for Cancer Research Pediatric Cancer Working Group met to update those guidelines with a review of more recently published evidence and risk estimates.

• #41 Children’s Hospital of Philadelphia Researchers Recommend New Standard of Care for Families with Hereditary Neuroblastoma Linked to ALK Mutation

  https://www.prnewswire.com/news-releases/childrens-hospital-of-philadelphia-researchers-recommend-new-standard-of-care-for-families-with-hereditary-neuroblastoma-linked-to-alk-mutation-302447385.html

  Researchers at Children’s Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common childhood cancer. […] The authors say the report could change how hereditary neuroblastoma for patients with an ALK mutation is treated and followed. They recommend ALK inhibitors as a frontline therapy for patients with the inherited mutations, potentially reducing the need for intensive chemotherapy and surgery. […] They also stress the importance of lifelong monitoring, challenging current guidelines that end surveillance in childhood.

• #42 Children’s Hospital of Philadelphia Researchers Recommend New Standard of Care for Families with Hereditary Neuroblastoma Linked to ALK Mutation | Newswise

  https://www.newswise.com/articles/children-s-hospital-of-philadelphia-researchers-recommend-new-standard-of-care-for-families-with-hereditary-neuroblastoma-linked-to-alk-mutation

  Researchers at Childrens Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common childhood cancer. […] The authors say the report could change how hereditary neuroblastoma for patients with an ALK mutation is treated and followed. They recommend ALK inhibitors as a frontline therapy for patients with the inherited mutations, potentially reducing the need for intensive chemotherapy and surgery. […] They also stress the importance of lifelong monitoring, challenging current guidelines that end surveillance in childhood.

• #43 Neuroblastoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK448111/

  Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months. It accounts for 15% of pediatric cancer-related deaths. The annual incidence of neuroblastoma in the United States is approximately 650 cases, i.e., 10.2 per million children (65 per million infants), with little change (0.4%) over time. While an overall improvement in five-year mortality has been noted between 1975 through 2005, subgroup-specific mortality paints a different picture. […] The widespread variability in neuroblastoma tumor behavior is linked to multiple factors now linked with patient prognosis. Classic prognostic categorization by Childrens Oncology Group (COG) divides patients into four groups based on patient age, post-surgical stage, MYCN amplification, histology, and DNA ploidy. Over 50% of newly diagnosed neuroblastoma are very-low or low-risk. Negative prognostic markers include age older than 18 months, metastasis at diagnosis, and presence of MYCN amplification, 1p loss, 11q loss, 17q gain, or DNA copy number alterations.

• #44 Neuroblastoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK448111/

  Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months. It accounts for 15% of pediatric cancer-related deaths. The annual incidence of neuroblastoma in the United States is approximately 650 cases, i.e., 10.2 per million children (65 per million infants), with little change (0.4%) over time. While an overall improvement in five-year mortality has been noted between 1975 through 2005, subgroup-specific mortality paints a different picture. […] The widespread variability in neuroblastoma tumor behavior is linked to multiple factors now linked with patient prognosis. Classic prognostic categorization by Childrens Oncology Group (COG) divides patients into four groups based on patient age, post-surgical stage, MYCN amplification, histology, and DNA ploidy. Over 50% of newly diagnosed neuroblastoma are very-low or low-risk. Negative prognostic markers include age older than 18 months, metastasis at diagnosis, and presence of MYCN amplification, 1p loss, 11q loss, 17q gain, or DNA copy number alterations.

• #45 Neuroblastoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK448111/

  Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months. It accounts for 15% of pediatric cancer-related deaths. The annual incidence of neuroblastoma in the United States is approximately 650 cases, i.e., 10.2 per million children (65 per million infants), with little change (0.4%) over time. While an overall improvement in five-year mortality has been noted between 1975 through 2005, subgroup-specific mortality paints a different picture. […] The widespread variability in neuroblastoma tumor behavior is linked to multiple factors now linked with patient prognosis. Classic prognostic categorization by Childrens Oncology Group (COG) divides patients into four groups based on patient age, post-surgical stage, MYCN amplification, histology, and DNA ploidy. Over 50% of newly diagnosed neuroblastoma are very-low or low-risk. Negative prognostic markers include age older than 18 months, metastasis at diagnosis, and presence of MYCN amplification, 1p loss, 11q loss, 17q gain, or DNA copy number alterations.

• #46 Neuroblastoma – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK448111/

  Neuroblastoma is the most common tumor of the sympathetic nervous system (97%) and the most common malignancy of infancy with a median age of diagnosis of 17 months. It accounts for 15% of pediatric cancer-related deaths. The annual incidence of neuroblastoma in the United States is approximately 650 cases, i.e., 10.2 per million children (65 per million infants), with little change (0.4%) over time. While an overall improvement in five-year mortality has been noted between 1975 through 2005, subgroup-specific mortality paints a different picture. […] The widespread variability in neuroblastoma tumor behavior is linked to multiple factors now linked with patient prognosis. Classic prognostic categorization by Childrens Oncology Group (COG) divides patients into four groups based on patient age, post-surgical stage, MYCN amplification, histology, and DNA ploidy. Over 50% of newly diagnosed neuroblastoma are very-low or low-risk. Negative prognostic markers include age older than 18 months, metastasis at diagnosis, and presence of MYCN amplification, 1p loss, 11q loss, 17q gain, or DNA copy number alterations.

• #47 Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants

  https://www.mdpi.com/2072-6694/14/19/4548

  High-risk neuroblastomas (HR-NB) are malignant tumors of childhood that are treated with a very aggressive and life-threatening approach; this includes autologous hemopoietic stem cell transplantation (HSCT) and the infusion of a mAb targeting the GD2 tumor-associated antigen. […] HR-NBs can be defined by the presence of metastatic disease in children older than 12/18 months or by the MYCN amplification in patients of any age. […] Current therapy showed benefits with a 5-year overall survival of up to 50%. However, it is associated with short and/or long-term side effects; these include neurological symptoms, renal, pancreatic, and thyroid dysfunction, poor growth, abnormal pubertal progression, infertility, and, for long-term survivors, increased risk of secondary solid or hematological malignancies.

• #48 Orphanet: Neuroblastoma

  https://www.orpha.net/en/disease/detail/635

  Neuroblastoma is a malignant tumor of neural crest cells, the cells that give rise to the sympathetic nervous system, which is observed in children. […] It represents about 10% of solid tumors in infants and children under the age of 15, with an annual incidence of about 1/70,000 in children in this class of age. […] In 90% of cases the neuroblastoma is diagnosed before the age of five. […] At the time of diagnosis, metastatic forms represent about 50% of cases. […] The majority of localized tumors have an excellent prognosis after surgery. […] In contrast, approximately 60% of children older than one year with neuroblastoma present metastatic disease at diagnosis with poor outcome, even with intensive treatment.

• #49 Neuroblastoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq

  Neuroblastoma is the most common extracranial solid tumor in childhood. More than 650 cases are diagnosed each year in the United States. The prevalence is about 1 case per 7,000 live births. The incidence is 8.3 cases per 1 million per year in children younger than 15 years. The overall incidence of neuroblastoma cases in the United States has remained stable. About 37% of patients are diagnosed as infants, and 90% are younger than 5 years at diagnosis, with a median age at diagnosis of 17 months. The data on age at diagnosis show that this is a disease of infancy, with the highest rate of diagnosis in the first month of life. […] The United States Cancer Statistics database and the National Program of Cancer Registries survival database were used to describe epidemiological trends in incidence and outcomes in patients with neuroblastoma between 2003 and 2019. Non-Hispanic White patients have a higher risk of developing neuroblastoma than all other race and ethnicity groups. Compared with non-Hispanic White patients, the relative risks were 0.54 for Hispanic patients, 0.64 for non-Hispanic Asian or Pacific Islander patients, 0.69 for non-Hispanic American Indian and Alaska Native patients, and 0.73 for non-Hispanic Black patients. The 5-year relative survival rates were higher for non-Hispanic White patients (80.7%) and Hispanic patients (80.8%), compared with non-Hispanic Black patients (72.6%). […] Findings from epidemiological studies have not unequivocally linked environmental or other exposures to increased or decreased incidences of neuroblastoma.

• #50 Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants

  https://www.mdpi.com/2072-6694/14/19/4548

  High-risk neuroblastomas (HR-NB) are malignant tumors of childhood that are treated with a very aggressive and life-threatening approach; this includes autologous hemopoietic stem cell transplantation (HSCT) and the infusion of a mAb targeting the GD2 tumor-associated antigen. […] HR-NBs can be defined by the presence of metastatic disease in children older than 12/18 months or by the MYCN amplification in patients of any age. […] Current therapy showed benefits with a 5-year overall survival of up to 50%. However, it is associated with short and/or long-term side effects; these include neurological symptoms, renal, pancreatic, and thyroid dysfunction, poor growth, abnormal pubertal progression, infertility, and, for long-term survivors, increased risk of secondary solid or hematological malignancies.

• #51 Researchers recommend new standard of care for families with hereditary neuroblastoma linked to ALK mutation

  https://medicalxpress.com/news/2025-05-standard-families-hereditary-neuroblastoma-linked.html

  Researchers at Children’s Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common childhood cancer. […] Despite significant advances in the treatment of high-risk neuroblastoma, the 5-year survival rate after diagnosis remains less than 50%. […] The authors say the report could change how hereditary neuroblastoma for patients with an ALK mutation is treated and followed. They recommend ALK inhibitors as a frontline therapy for patients with the inherited mutations, potentially reducing the need for intensive chemotherapy and surgery. […] They also stress the importance of lifelong monitoring, challenging current guidelines that end surveillance in childhood.

• #52 Pediatric Neuroblastoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988284-followup

  Patients are periodically monitored in the clinic after each course of therapy to monitor for complications and to assess response to therapy with diagnostic imaging. […] After completion of therapy, successfully treated patients require follow-up care and close surveillance for any signs or symptoms of recurrent disease. Follow-up care includes monitoring of urinary catecholamines, physical examination, and diagnostic imaging. […] Because most recurrences occur during the first 2 years following treatment, most protocols recommend close follow-up care during this interval. […] Long-term follow-up care to assess impact of therapy on growth, development, and organ toxicity is essential. […] The cause of neuroblastoma is unknown. No specific environmental exposure or risk factors have been identified.

• #53 Pediatric Neuroblastoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988284-followup

  Patients are periodically monitored in the clinic after each course of therapy to monitor for complications and to assess response to therapy with diagnostic imaging. […] After completion of therapy, successfully treated patients require follow-up care and close surveillance for any signs or symptoms of recurrent disease. Follow-up care includes monitoring of urinary catecholamines, physical examination, and diagnostic imaging. […] Because most recurrences occur during the first 2 years following treatment, most protocols recommend close follow-up care during this interval. […] Long-term follow-up care to assess impact of therapy on growth, development, and organ toxicity is essential. […] The cause of neuroblastoma is unknown. No specific environmental exposure or risk factors have been identified.

• #54 Pediatric Neuroblastoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988284-followup

  Patients are periodically monitored in the clinic after each course of therapy to monitor for complications and to assess response to therapy with diagnostic imaging. […] After completion of therapy, successfully treated patients require follow-up care and close surveillance for any signs or symptoms of recurrent disease. Follow-up care includes monitoring of urinary catecholamines, physical examination, and diagnostic imaging. […] Because most recurrences occur during the first 2 years following treatment, most protocols recommend close follow-up care during this interval. […] Long-term follow-up care to assess impact of therapy on growth, development, and organ toxicity is essential. […] The cause of neuroblastoma is unknown. No specific environmental exposure or risk factors have been identified.

• #55 Pediatric Neuroblastoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988284-followup

  Patients are periodically monitored in the clinic after each course of therapy to monitor for complications and to assess response to therapy with diagnostic imaging. […] After completion of therapy, successfully treated patients require follow-up care and close surveillance for any signs or symptoms of recurrent disease. Follow-up care includes monitoring of urinary catecholamines, physical examination, and diagnostic imaging. […] Because most recurrences occur during the first 2 years following treatment, most protocols recommend close follow-up care during this interval. […] Long-term follow-up care to assess impact of therapy on growth, development, and organ toxicity is essential. […] The cause of neuroblastoma is unknown. No specific environmental exposure or risk factors have been identified.

• #56 Pediatric Neuroblastoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988284-followup

  Patients are periodically monitored in the clinic after each course of therapy to monitor for complications and to assess response to therapy with diagnostic imaging. […] After completion of therapy, successfully treated patients require follow-up care and close surveillance for any signs or symptoms of recurrent disease. Follow-up care includes monitoring of urinary catecholamines, physical examination, and diagnostic imaging. […] Because most recurrences occur during the first 2 years following treatment, most protocols recommend close follow-up care during this interval. […] Long-term follow-up care to assess impact of therapy on growth, development, and organ toxicity is essential. […] The cause of neuroblastoma is unknown. No specific environmental exposure or risk factors have been identified.

• #57 Pediatric Neuroblastoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988284-followup

  Patients are periodically monitored in the clinic after each course of therapy to monitor for complications and to assess response to therapy with diagnostic imaging. […] After completion of therapy, successfully treated patients require follow-up care and close surveillance for any signs or symptoms of recurrent disease. Follow-up care includes monitoring of urinary catecholamines, physical examination, and diagnostic imaging. […] Because most recurrences occur during the first 2 years following treatment, most protocols recommend close follow-up care during this interval. […] Long-term follow-up care to assess impact of therapy on growth, development, and organ toxicity is essential. […] The cause of neuroblastoma is unknown. No specific environmental exposure or risk factors have been identified.

• #58 CHOP Researchers Show Liquid Biopsies Can Catch Disease Progression Early in High-Risk Neuroblastoma | Children’s Hospital of Philadelphia

  https://www.chop.edu/news/chop-researchers-show-liquid-biopsies-can-catch-disease-progression-early-high-risk

  Neuroblastoma is an aggressive pediatric cancer that develops from early nerve cells and accounts for up to 10% of childhood cancer deaths. Survival rates are low less than 50% of patients with the disease survive, and less than 5% with relapsed disease overcome it. […] To circumvent this challenge, researchers at Childrens Hospital of Philadelphia (CHOP) investigated whether a series of liquid biopsies performed in partnership with Foundation Medicine could less invasively and more accurately identify tumor changes in patients with high-risk neuroblastoma. […] The evolution of these tumors happens just before or at the same time as disease progression, showing that ctDNA profiling can identify clinically relevant genomic evolution perhaps even earlier than current standard disease surveillance methods.

• #59 CHOP Researchers Show Liquid Biopsies Can Catch Disease Progression Early in High-Risk Neuroblastoma | Children’s Hospital of Philadelphia

  https://www.chop.edu/news/chop-researchers-show-liquid-biopsies-can-catch-disease-progression-early-high-risk

  Based on our observations, we suggest that serial ctDNA profiling should be integrated into clinical practice for children with high-risk neuroblastoma to provide real-time data on genomic evolution and insights into mechanisms of therapy resistance, in addition to potentially identifying clinically targetable mutations. […] In time, ctDNA profiling could allow for decreased use of standard radiographic methods used for disease surveillance, many of which require analgesia along with continued exposure to radiation for children who are already at high risk for development of secondary malignancies.

• #60 A new era for treating high-risk neuroblastoma – research advances to look out for in 2024

  https://www.icr.ac.uk/research-and-discoveries/cancer-blogs/detail/science-talk/a-new-era-for-treating-high-risk-neuroblastoma-research-advances-to-look-out-for-in-2024

  Neuroblastoma is the most common childhood cancer, and each year, around 100 families will receive the terrible news that their child has been diagnosed. […] Treatment for neuroblastoma depends on the aggressiveness of the tumour. Although many children will be cured after chemotherapy and surgery, around half of children will have what is considered high-risk disease. […] In the UK, most children diagnosed with neuroblastoma will receive their treatment at specialist cancer centres on clinical trials, which are constantly adapting to advances. […] Last year was a big year for clinical trials in neuroblastoma, with several new treatments showing promise against the disease. […] The phase I trial looked at giving lorlatinib either alone or in combination with chemotherapy to both children and adults with ALK-positive neuroblastoma that had relapsed on standard treatments.

• #61 A new era for treating high-risk neuroblastoma – research advances to look out for in 2024

  https://www.icr.ac.uk/research-and-discoveries/cancer-blogs/detail/science-talk/a-new-era-for-treating-high-risk-neuroblastoma-research-advances-to-look-out-for-in-2024

  Following these results, from next year, all children newly diagnosed with neuroblastoma with ALK mutations will receive lorlatinib as a first line treatment as part of a phase III clinical trial, to be conducted in both North America and Europe. […] Larger clinical trials are continuing to explore the safety, benefits and feasibility of using CAR-T therapy in neuroblastoma. […] The study, led by the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham, involved 160 children and young people across Europe. […] The findings were published in the Journal of Clinical Oncology, and the combination treatment has already been incorporated into the UK standard of care guidelines for neuroblastoma treatment, meaning all eligible children will receive bevacizumab as part of a clinical trial.

• #62 Children’s Hospital of Philadelphia Researchers Recommend New Standard of Care for Families with Hereditary Neuroblastoma Linked to ALK Mutation | Newswise

  https://www.newswise.com/articles/children-s-hospital-of-philadelphia-researchers-recommend-new-standard-of-care-for-families-with-hereditary-neuroblastoma-linked-to-alk-mutation

  Researchers at Childrens Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common childhood cancer. […] The authors say the report could change how hereditary neuroblastoma for patients with an ALK mutation is treated and followed. They recommend ALK inhibitors as a frontline therapy for patients with the inherited mutations, potentially reducing the need for intensive chemotherapy and surgery. […] They also stress the importance of lifelong monitoring, challenging current guidelines that end surveillance in childhood.

• #63 Researchers recommend new standard of care for families with hereditary neuroblastoma linked to ALK mutation

  https://medicalxpress.com/news/2025-05-standard-families-hereditary-neuroblastoma-linked.html

  Researchers at Children’s Hospital of Philadelphia (CHOP) highlighted the success of anaplastic lymphoma kinase (ALK) inhibition therapy in treating hereditary neuroblastoma, a rare subset of a common childhood cancer. […] Despite significant advances in the treatment of high-risk neuroblastoma, the 5-year survival rate after diagnosis remains less than 50%. […] The authors say the report could change how hereditary neuroblastoma for patients with an ALK mutation is treated and followed. They recommend ALK inhibitors as a frontline therapy for patients with the inherited mutations, potentially reducing the need for intensive chemotherapy and surgery. […] They also stress the importance of lifelong monitoring, challenging current guidelines that end surveillance in childhood.

• #64 Danyelza Added to NCCN Guidelines for High-Risk Neuroblastoma

  https://www.curetoday.com/view/danyelza-added-to-nccn-guidelines-for-high-risk-neuroblastoma

  Danyelza is now a category 2a treatment for high-risk neuroblastoma, following positive trial results and FDA approval. […] Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of brain cancer. […] Danyelza is now recommended by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology as a NCCN category 2a treatment option for patients with high-risk neuroblastoma, a type of brain cancer, according to a news release from Y-mAbs Therapeutics. […] Neuroblastoma is a cancer that starts in immature nerve cells, often in the adrenal glands, abdomen, chest or near the spine. It most commonly affects children under five years old and is usually diagnosed as the tumor grows, causing symptoms.

• #65 Pediatric Neuroblastoma Follow-up: Further Outpatient Care, Further Inpatient Care, Inpatient & Outpatient Medications

  https://emedicine.medscape.com/article/988284-followup

  Patients are periodically monitored in the clinic after each course of therapy to monitor for complications and to assess response to therapy with diagnostic imaging. […] After completion of therapy, successfully treated patients require follow-up care and close surveillance for any signs or symptoms of recurrent disease. Follow-up care includes monitoring of urinary catecholamines, physical examination, and diagnostic imaging. […] Because most recurrences occur during the first 2 years following treatment, most protocols recommend close follow-up care during this interval. […] Long-term follow-up care to assess impact of therapy on growth, development, and organ toxicity is essential. […] The cause of neuroblastoma is unknown. No specific environmental exposure or risk factors have been identified.

• #66 Neuroblastoma Treatment (PDQ®) – NCI

  https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq

  Neuroblastoma is the most common extracranial solid tumor in childhood. More than 650 cases are diagnosed each year in the United States. The prevalence is about 1 case per 7,000 live births. The incidence is 8.3 cases per 1 million per year in children younger than 15 years. The overall incidence of neuroblastoma cases in the United States has remained stable. About 37% of patients are diagnosed as infants, and 90% are younger than 5 years at diagnosis, with a median age at diagnosis of 17 months. The data on age at diagnosis show that this is a disease of infancy, with the highest rate of diagnosis in the first month of life. […] The United States Cancer Statistics database and the National Program of Cancer Registries survival database were used to describe epidemiological trends in incidence and outcomes in patients with neuroblastoma between 2003 and 2019. Non-Hispanic White patients have a higher risk of developing neuroblastoma than all other race and ethnicity groups. Compared with non-Hispanic White patients, the relative risks were 0.54 for Hispanic patients, 0.64 for non-Hispanic Asian or Pacific Islander patients, 0.69 for non-Hispanic American Indian and Alaska Native patients, and 0.73 for non-Hispanic Black patients. The 5-year relative survival rates were higher for non-Hispanic White patients (80.7%) and Hispanic patients (80.8%), compared with non-Hispanic Black patients (72.6%). […] Findings from epidemiological studies have not unequivocally linked environmental or other exposures to increased or decreased incidences of neuroblastoma.

• #67

  https://link.springer.com/article/10.1023/A:1008998925889

  Objectives: We evaluated parental occupation and the risk of neuroblastoma using data from a large casecontrol study conducted by the Children’s Cancer Group and the Pediatric Oncology Group. […] Results: An increased risk of neuroblastoma was found for fathers employed as broadcast, telephone and dispatch operators (odds ratio [OR]=6.1; 95% confidence interval [CI]=0.750.9), electrical power installers and power plant operators (OR=2.7; CI=0.98.1), landscapers and groundskeepers (OR=2.3; CI=1.05.2), and painters (OR=2.1; CI=0.94.8). Elevated odds ratios were found for mothers employed as farmers and farm workers (OR=2.2; CI=0.68.8), florists and garden store workers (OR=2.4; CI=0.69.9), hairdressers and barbers (OR=2.8; CI=1.26.3), electric power installers and power plant operators, and sailors, fishers, and railroad workers.

• #68

  https://link.springer.com/article/10.1023/A:1008998925889

  Objectives: We evaluated parental occupation and the risk of neuroblastoma using data from a large casecontrol study conducted by the Children’s Cancer Group and the Pediatric Oncology Group. […] Results: An increased risk of neuroblastoma was found for fathers employed as broadcast, telephone and dispatch operators (odds ratio [OR]=6.1; 95% confidence interval [CI]=0.750.9), electrical power installers and power plant operators (OR=2.7; CI=0.98.1), landscapers and groundskeepers (OR=2.3; CI=1.05.2), and painters (OR=2.1; CI=0.94.8). Elevated odds ratios were found for mothers employed as farmers and farm workers (OR=2.2; CI=0.68.8), florists and garden store workers (OR=2.4; CI=0.69.9), hairdressers and barbers (OR=2.8; CI=1.26.3), electric power installers and power plant operators, and sailors, fishers, and railroad workers.

• #69

  https://link.springer.com/article/10.1023/A:1008998925889

  Objectives: We evaluated parental occupation and the risk of neuroblastoma using data from a large casecontrol study conducted by the Children’s Cancer Group and the Pediatric Oncology Group. […] Results: An increased risk of neuroblastoma was found for fathers employed as broadcast, telephone and dispatch operators (odds ratio [OR]=6.1; 95% confidence interval [CI]=0.750.9), electrical power installers and power plant operators (OR=2.7; CI=0.98.1), landscapers and groundskeepers (OR=2.3; CI=1.05.2), and painters (OR=2.1; CI=0.94.8). Elevated odds ratios were found for mothers employed as farmers and farm workers (OR=2.2; CI=0.68.8), florists and garden store workers (OR=2.4; CI=0.69.9), hairdressers and barbers (OR=2.8; CI=1.26.3), electric power installers and power plant operators, and sailors, fishers, and railroad workers.

• #70

  https://link.springer.com/article/10.1023/A:1008998925889

  Objectives: We evaluated parental occupation and the risk of neuroblastoma using data from a large casecontrol study conducted by the Children’s Cancer Group and the Pediatric Oncology Group. […] Results: An increased risk of neuroblastoma was found for fathers employed as broadcast, telephone and dispatch operators (odds ratio [OR]=6.1; 95% confidence interval [CI]=0.750.9), electrical power installers and power plant operators (OR=2.7; CI=0.98.1), landscapers and groundskeepers (OR=2.3; CI=1.05.2), and painters (OR=2.1; CI=0.94.8). Elevated odds ratios were found for mothers employed as farmers and farm workers (OR=2.2; CI=0.68.8), florists and garden store workers (OR=2.4; CI=0.69.9), hairdressers and barbers (OR=2.8; CI=1.26.3), electric power installers and power plant operators, and sailors, fishers, and railroad workers.

• #71

  https://link.springer.com/article/10.1023/A:1008998925889

  Conclusion: The study reinforced some prior evidence of increased risks in electrical, farming and gardening, and painting occupations, but failed to confirm other previously reported associations. Further analyses of exposure to electromagnetic fields, metals, solvents, and pesticides are currently under way.

• #72

  https://link.springer.com/article/10.1023/A:1008998925889

  Conclusion: The study reinforced some prior evidence of increased risks in electrical, farming and gardening, and painting occupations, but failed to confirm other previously reported associations. Further analyses of exposure to electromagnetic fields, metals, solvents, and pesticides are currently under way.

• #73 Advances In Neuroblastoma Risk Assessment and Treatment – BroadcastMed

  https://www.broadcastmed.com/5253/videos/advances-in-neuroblastoma-risk-assessment-and-treatment

  Neuroblastoma is a clinically heterogeneous disease. […] We currently tailor treatment according to the patient’s predicted clinical behavior. […] In the children’s oncology group we use a risk group schema that includes the patient’s stage, age, and mix status, tumor cell ploidy, histology, as well as some other characteristics, to classify patients into either low, intermediate or high risk groups. […] Unfortunately, patients who are classified as high risk continue to have relatively poor outcome. […] The INRG classification system will ensure that all children with neuroblastoma are stratified into homogeneous pre-treatment groups. […] It will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world. […] The database infrastructure has been successfully established at the University of Chicago.

• #74 Advances In Neuroblastoma Risk Assessment and Treatment – BroadcastMed

  https://www.broadcastmed.com/5253/videos/advances-in-neuroblastoma-risk-assessment-and-treatment

  Neuroblastoma is a clinically heterogeneous disease. […] We currently tailor treatment according to the patient’s predicted clinical behavior. […] In the children’s oncology group we use a risk group schema that includes the patient’s stage, age, and mix status, tumor cell ploidy, histology, as well as some other characteristics, to classify patients into either low, intermediate or high risk groups. […] Unfortunately, patients who are classified as high risk continue to have relatively poor outcome. […] The INRG classification system will ensure that all children with neuroblastoma are stratified into homogeneous pre-treatment groups. […] It will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world. […] The database infrastructure has been successfully established at the University of Chicago.

• #75 Advances In Neuroblastoma Risk Assessment and Treatment – BroadcastMed

  https://www.broadcastmed.com/5253/videos/advances-in-neuroblastoma-risk-assessment-and-treatment

  Links to genomic data in the INRG database will provide unparalleled resource for advancing our knowledge of the epidemiology, pathogenesis, and genetics of neuroblastoma. […] Analyzing large cohorts of patients will lead to more precise prognostication, the identification of new therapeutic targets, and ultimately more effective personalized therapeutic strategies for children with neuroblastoma.

• #76 Advances In Neuroblastoma Risk Assessment and Treatment – BroadcastMed

  https://www.broadcastmed.com/5253/videos/advances-in-neuroblastoma-risk-assessment-and-treatment

  Links to genomic data in the INRG database will provide unparalleled resource for advancing our knowledge of the epidemiology, pathogenesis, and genetics of neuroblastoma. […] Analyzing large cohorts of patients will lead to more precise prognostication, the identification of new therapeutic targets, and ultimately more effective personalized therapeutic strategies for children with neuroblastoma.

• #77 A new era for treating high-risk neuroblastoma – research advances to look out for in 2024

  https://www.icr.ac.uk/research-and-discoveries/cancer-blogs/detail/science-talk/a-new-era-for-treating-high-risk-neuroblastoma-research-advances-to-look-out-for-in-2024

  With global efforts to improve the lives of children diagnosed with neuroblastoma, we’re confident that the coming decades will bring a new pipeline of discoveries and new treatments. […] The SMPaeds2 initiative involves analysing children’s tumours in even more detail to uncover new insights into the biology of the disease and pave the way to better precision medicines.

• #78 A new era for treating high-risk neuroblastoma – research advances to look out for in 2024

  https://www.icr.ac.uk/research-and-discoveries/cancer-blogs/detail/science-talk/a-new-era-for-treating-high-risk-neuroblastoma-research-advances-to-look-out-for-in-2024

  With global efforts to improve the lives of children diagnosed with neuroblastoma, we’re confident that the coming decades will bring a new pipeline of discoveries and new treatments. […] The SMPaeds2 initiative involves analysing children’s tumours in even more detail to uncover new insights into the biology of the disease and pave the way to better precision medicines.

Zobacz więcej